SCHEMBL21763585

SCHEMBL21763585

CCCC(C)NCc1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
ALDH1A1 P00352 4/20 0.51
NPSR1 Q6W5P4 1/20 0.51
PKM P14618 2/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LTA4H P09960 1/20 0.46
RAD52 P43351 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
CHRM2 P08172 1/20 0.45
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19954195 1.00 CYP1A2 (0.53) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL10559849 0.89 TDP1 (0.55) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL171029 0.87 CYP1A2 (0.56) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL6645277 0.87 CYP1A2 (0.56) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL19334592 0.83 CYP1A2 (0.51) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL13995928 0.82 CYP1A2 (0.55) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL10864606 0.82 CYP1A2 (0.55) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL30729674 0.82 CYP1A2 (0.55) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL13995941 0.82 CYP1A2 (0.55) CYP1A2CYP2D6ALDH1A1NPSR1PKM
SCHEMBL104748 0.81 CYP1A2 (0.62) CYP1A2CYP2D6ALDH1A1NPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496230-B1 IRE-1 ALPHA INHIBITORS FOSUN ORINOVE PHARMATECH INC (CN) 2020-02-26 EP disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 US disclosed